Menu
Share this

PPD Recognized for Training Programs Advancing Clinical Research

Driving innovation for biopharmaceutical clients by harnessing human capital

04 Feb. 2014

RSS

WILMINGTON, N.C. (February 4, 2014) – Pharmaceutical Product Development, LLC (PPD) today announced the company was ranked among the top U.S. businesses for employee learning and development by Training magazine. The recognition marks the third consecutive ranking for PPD on the annual Training Top 125 list, and the contract research organization (CRO) was honored Feb. 3 during the Training 2014 Conference & Expo in San Diego, Calif.

PPD incorporates a holistic and integrated approach to continuous learning that optimizes processes, leverages technology, trains and develops staff, and measures performance. PPD’s approach to employee development helps ensure that clinical trials for promising new medical therapies are conducted ethically, efficiently and with the highest standards of data quality, while focusing on patient safety. For more than 20 years, PPD has designed, developed and implemented a wide-range of learning and performance programs tailored to clients’ needs.

“PPD’s learning and development programs enhance the skills and knowledge our employees bring to the sophisticated clinical studies conducted in today’s rapidly evolving research environment,” said Mike Wilkinson, PPD’s chief information officer and executive vice president. “We deploy pioneering technology and the latest methods to provide training across multiple platforms – from traditional instructor-led classroom settings to virtual environments, podcasts, social media and mobile devices – that facilitate learning on demand.”

At PPD, employee learning and development spans leadership and high-potential development, key talent programs, technical skills, job specific training and individual contributor soft skills training, all of which is integrated and aligned to business goals and objectives under the leadership of a global learning council. Key training includes PPD’s industry-leading clinical foundation program for clinical research associates (CRAs) that addresses theoretical knowledge and practical application, followed by performance-based assessment. PPD enhanced the clinical foundation program by developing and implementing PPD® 3D, an award-winning, virtual training world that simulates field experiences for CRAs.

“The 2014 Training Top 125 winners demonstrated an unrelenting focus on effective training and employee development tied to corporate strategic goals and measurable results,” said Lorri Freifeld, editor-in-chief of Training magazine. “The competition was especially strong this year.”

The Training Top 125 ranking, now in its 14th year, is based on benchmarking statistics such as total training budget; percentage of payroll; number of training hours per employee program; goals, evaluation, measurement and workplace surveys; hours of training per employee annually; and detailed formal programs.

About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.

Contacts
Media:
Lee Kennedy
+1 919 456 5350
lee.kennedy@ppdi.com

Investors:
Luke Heagle
+1 910 558 7585
luke.heagle@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s Training Top 125 award and learning and development programs, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.